Abstracts tagged "methotrexate (MTX)"

Abstract Number: 2522 • 2016 ACR/ARHP Annual Meeting
Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response
Carles Ubeda¹, Shahla Abdollahi-Roodsaz², Steven B. Abramson³ and Jose U. Scher⁴, ¹Institute for Research in Public Health, Valencia, Spain, ²Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in the therapeutics of inflammatory arthritides, methotrexate (MTX) remains the mainstay of treatment for rheumatoid arthritis (RA) and related conditions worldwide.…
Abstract Number: 23 • 2016 ACR/ARHP Annual Meeting
Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: The prevalence and characteristics of patients with nonalcoholic fatty liver disease (NAFLD) have not been well characterized in the RA population. The purpose of…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
Abstract Number: 565 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Gastrointestinal Tolerance in Patients with Rheumatoid Arthritis and Methotrexate Daily Doses
Adriana Nallely Rangel-Botello¹, Marco Ulises Martinez-Martinez², Carlos Abud Mendoza¹, Alexa Bazua Gerez³, Ángel Cárdenas Hernández³, Luis Domínguez Salgado³, José Espinoza Martínez³, Héctor García González³, Oswaldo González Rivera³, Gustavo Hernández de la Cruz³, Germán Magaña Ávila³, Miguel Martínez Rojas³ and Mariana Moctezuma Dávila³, ¹Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ²Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ³Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. We reported the liver safety with daily dose of MTX1. Weekly doses of MTX…
Abstract Number: 2561 • 2016 ACR/ARHP Annual Meeting
A Novel Pharmacological Action of MTX on RA Fibroblast-like Synoviocytes Via Circadian Clock Genes
Kohjin Suzuki¹, Kohsuke Yoshida¹, Teppei Hashimoto², Kenta Kaneshiro¹, Ayako Nakai¹, Naonori Hashimoto¹, Yoshiko Kawasaki², Nao Shibanuma³, Natsuko Nakagawa⁴, Yoshitada Sakai⁵ and Akira Hashiramoto⁶, ¹Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, ³Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁴Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, ⁵Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: The circadian rhythm is disrupted in patients with rheumatoid arthritis (RA), and we have shown that tumor necrosis factor(TNF)-ƒ¿ inhibits the expression of circadian…
Abstract Number: 645 • 2016 ACR/ARHP Annual Meeting
Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
René-Marc Flipo¹, Cécile Gaujoux-Viala², Christophe Hudry^3,4, Elena Zinovieva⁵, Eric Leutenegger⁶ and Hélène Herman-Demars⁵, ¹Rheumatology Department, Lille University Hospital Roger Salengro, Lille, France, ²Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology Institute, 75008, France, ⁵Medical Department Nordic Pharma, Paris, France, ⁶GECEM, Montrouge, France
Background/Purpose: Current guidelines consider MTX as initial gold standard treatment for patients (pts) with RA. They also propose various strategies for MTX inadequate responders, among…
Abstract Number: 2637 • 2016 ACR/ARHP Annual Meeting
Clinical Trials Aiming to Prevent the Development of Rheumatoid Arthritis Cannot Detect Prevention without Adequate Risk Stratification; A Trial Performed in UA-Patients As Example
Leonie E Burgers, Cornelia F Allaart, Tom WJ Huizinga and Annette HM van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Prevention of rheumatoid arthritis (RA) was the aim of several clinical trials performed in undifferentiated arthritis (UA). Overall these trials had negative results. As…
Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
James R. O'Dell¹, Melanie Rohr¹, Stanley B. Cohen², J Carter Thorne³ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…
Abstract Number: 2138 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Richard Leff¹, Sunil Kumar², Natalia Nikulenkova³, Igor Kaidashev⁴, Kerstin Allen⁵, Joi Dunbar⁶, Howard Stern⁷, Julian Adams⁶ and Michael Weinblatt⁸, ¹Clinical Research, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Centre for Clinical Research and Effective Practice (CCRep), Auckland, New Zealand, ³State Budgetary Healthcare Institution of Vladimir Region, Regional Clinical Hospital, Vladimir, Russia, ⁴City Clinical Hospital #1 of Poltava City, Poltava, Ukraine, ⁵Biostatistics, Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁶Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁷Translational Science, Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Duvelisib is a potent, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ,γ being developed for hematologic malignancies, and was also explored in early phase studies in…
Abstract Number: 187 • 2015 ACR/ARHP Annual Meeting
Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound
Kazuhiro Yokota¹, Takuma Tsuzuki Wada², Yuji Akiyama² and Toshihide Mimura³, ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Irama, Japan, ²Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: The detection of power Doppler (PD) ultrasound signals in joints may be considered as the presence of joint inflammation, i.e., synovitis which is a…
Abstract Number: 2671 • 2015 ACR/ARHP Annual Meeting
Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis
Abhijeet Danve¹, Harlan Sayles², Ted R. Mikuls³ and James R. O'Dell², ¹Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate (MTX) is routinely used as the first-line drug for rheumatoid arthritis (RA). About 1 in 3 RA patients achieve excellent RA control with…
Abstract Number: 432 • 2015 ACR/ARHP Annual Meeting
Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-
Tadashi Okano¹, Kentaro Inui², Masahiro Tada³, Yuko Sugioka⁴, Kenji Mamoto¹, Tatsuya Koike⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopedic surgery, Osaka City General Hospital, Osaka, Japan, ⁴Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: The latest recommendations for the treatment of rheumatoid arthritis (RA) focus on the achievement of clinical remission. However, joints with subclinical positive power Doppler…
Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting
The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Norman B. Gaylis¹, Steven Needell² and Joanne Sagliani¹, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology Group, Boca Raton, FL
Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…
Abstract Number: 439 • 2015 ACR/ARHP Annual Meeting
Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials
Tanja Schjødt Jørgensen¹, Simon Tarp¹, Daniel E. Furst², Anna Døssing¹, Peter C. Taylor³, Henning Bliddal¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose : One of the frequently claimed advantages of biologic agents is their potential to arrest radiographic progression. The ability of disease-modifying antirheumatic drugs (DMARDs;…
Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Roy Fleischmann¹, T. W. J. Huizinga², Arthur Kavanaugh³, Bethanie Wilkinson⁴, Kenneth Kwok⁵, Ryan DeMasi⁵ and Ronald F. van Vollenhoven⁶, ¹Metroplex Clinical Research Center, Dallas, TX, ²Leiden University Medical Center, Leiden, Netherlands, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.